Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 7/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 4/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22637858 | 1.00 | KCNT1 (0.60) | KCNT1TDP1ACACBPPARDPPARA | |
| SCHEMBL22649224 | 1.00 | KCNT1 (0.60) | KCNT1TDP1ACACBPPARDPPARA | |
| SCHEMBL29463519 | 1.00 | KCNT1 (0.60) | KCNT1TDP1ACACBPPARDPPARA | |
| SCHEMBL22649547 | 1.00 | KCNT1 (0.60) | KCNT1TDP1ACACBPPARDPPARA | |
| SCHEMBL22637514 | 0.90 | KCNT1 (0.54) | KCNT1TDP1IDH1LMNATSHR | |
| SCHEMBL24660553 | 0.89 | KCNT1 (0.47) | KCNT1TDP1ACACBPPARDPPARA | |
| SCHEMBL14153113 | 0.89 | KCNT1 (0.49) | KCNT1ACACBPPARDPPARAIDH1 | |
| SCHEMBL24660736 | 0.88 | KCNT1 (0.48) | KCNT1TDP1ACACBPPARDPPARA | |
| SCHEMBL22649167 | 0.88 | KCNT1 (0.57) | KCNT1TDP1ACACBPPARDPPARA | |
| SCHEMBL22649477 | 0.88 | PPARD (0.49) | KCNT1TDP1ACACBPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | KCNT1 1/4885TDP1 1280/4885ACACB 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.